SCHEMBL108678

SCHEMBL108678

c1cc2c(cc1CN1CCN(Cc3ccc4c(c3)OCO4)CC1)OCO2

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.70
CYP2D6 P10635 2/20 0.70
MEN1 O00255 1/20 0.70
USP2 O75604 1/20 0.70
CYP1A2 P05177 1/20 0.70
CYP3A4 P08684 1/20 0.70
HTR1A P08908 1/20 0.70
ADRA2A P08913 1/20 0.70
DRD2 P14416 1/20 0.70
ADRA2B P18089 1/20 0.70
ADRA2C P18825 1/20 0.70
NFKB1 P19838 1/20 0.70
SLC6A2 P23975 1/20 0.70
MAPK1 P28482 1/20 0.70
SLC6A4 P31645 1/20 0.70
CYP2C19 P33261 1/20 0.70
ADRA1A P35348 1/20 0.70
DRD3 P35462 1/20 0.70
HTR2B P41595 1/20 0.70
KMT2A Q03164 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8170046 0.93 KDM4E (0.62) KDM4ECYP2D6MEN1USP2CYP1A2
SCHEMBL8286300 0.92 KDM4E (0.62) KDM4ECYP2D6MEN1USP2CYP1A2
SCHEMBL19300185 0.92 CYP2D6 (0.63) KDM4ECYP2D6MEN1USP2CYP1A2
SCHEMBL22005473 0.92 KDM4E (0.62) KDM4ECYP2D6MEN1USP2CYP1A2
SCHEMBL2316901 0.92 CYP2D6 (0.82) KDM4ECYP2D6MEN1USP2CYP1A2
SCHEMBL19300219 0.92 KDM4E (0.62) KDM4ECYP2D6MEN1USP2CYP1A2
SCHEMBL2056152 0.92 KDM4E (0.62) KDM4ECYP2D6MEN1USP2CYP1A2
SCHEMBL13062752 0.92 ALDH1A1 (0.64) KDM4ECYP2D6MEN1USP2CYP1A2
SCHEMBL6482711 0.91 MEN1 (0.61) KDM4ECYP2D6MEN1USP2CYP1A2
SCHEMBL4753138 0.90 MEN1 (0.66) KDM4ECYP2D6MEN1USP2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4264770-A Process for preparing 1,4-bis-piperonylpiperazine and similar compounds FARMACEUTICI GEYMONAT SUD S.P.A. (IT) 1981-04-28 US claimed
US-4225714-A Process for preparing p-chlorophenoxy-acetyl-piperonylpiperazine hydrochloride FARMACEUTICI GEYMONAT SUD S.P.A. (IT) 1980-09-30 US claimed
US-10435394-B2 Plant growth-promotion agent and method for promoting plant growth RIKEN (JP) 2019-10-08 US disclosed
US-10435394-B2 Plant growth-promotion agent and method for promoting plant growth RIKEN (JP) 2019-10-08 US disclosed
US-20170305886-A1 PLANT GROWTH-PROMOTION AGENT AND METHOD FOR PROMOTING PLANT GROWTH RIKEN (JP) 2017-10-26 US disclosed
US-20170305886-A1 PLANT GROWTH-PROMOTION AGENT AND METHOD FOR PROMOTING PLANT GROWTH RIKEN (JP) 2017-10-26 US disclosed
US-20170305886-A1 PLANT GROWTH-PROMOTION AGENT AND METHOD FOR PROMOTING PLANT GROWTH RIKEN (JP) 2017-10-26 US disclosed
US-9051253-B2 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's PROTEOTECH INC. (US) 2015-06-09 US disclosed
US-9051253-B2 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's PROTEOTECH INC. (US) 2015-06-09 US disclosed
US-9051253-B2 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's PROTEOTECH INC. (US) 2015-06-09 US disclosed
US-8895554-B2 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and Parkinson's disease PROTEOTECH INC (US) 2014-11-25 US disclosed
EP-1511710-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER S DISEASE, TYPE 2 DIABETES, AND PARKINSON S DISEASE Proteotech, Inc. (US) 2005-03-09 EP disclosed
US-20040127555-A1 bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis PROTAMED, INC. 2004-07-01 US disclosed
WO-2003101927-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE PROTEOTECH, INC. (US) 2003-12-11 WO disclosed
WO-2003101927-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE PROTEOTECH, INC. (US) 2003-12-11 WO disclosed
US-4264770-A Process for preparing 1,4-bis-piperonylpiperazine and similar compounds FARMACEUTICI GEYMONAT SUD S.P.A. (IT) 1981-04-28 US disclosed
US-4264770-A Process for preparing 1,4-bis-piperonylpiperazine and similar compounds FARMACEUTICI GEYMONAT SUD S.P.A. (IT) 1981-04-28 US disclosed
US-4264770-A Process for preparing 1,4-bis-piperonylpiperazine and similar compounds FARMACEUTICI GEYMONAT SUD S.P.A. (IT) 1981-04-28 US disclosed
US-4225714-A Process for preparing p-chlorophenoxy-acetyl-piperonylpiperazine hydrochloride FARMACEUTICI GEYMONAT SUD S.P.A. (IT) 1980-09-30 US disclosed
US-4225714-A Process for preparing p-chlorophenoxy-acetyl-piperonylpiperazine hydrochloride FARMACEUTICI GEYMONAT SUD S.P.A. (IT) 1980-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10435394-B2 Plant growth-promotion agent and method for promoting plant growth NPR1, NAT1, NOS1 KDM4E 3307/4885CYP2D6 4522/4885MEN1 1168/4885
US-20040127555-A1 bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; treatment of A beta , IAPP, other amyloids, and alpha -synuclein or NAC fibrillogenesis IAPP, SNCA, IDE KDM4E 4549/4885CYP2D6 2754/4885MEN1 3591/4885
US-20170305886-A1 PLANT GROWTH-PROMOTION AGENT AND METHOD FOR PROMOTING PLANT GROWTH NPR1, NAT1, NOS1 KDM4E 3307/4885CYP2D6 4522/4885MEN1 1168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.